[go: up one dir, main page]

CL2018000246A1 - Tableta - Google Patents

Tableta

Info

Publication number
CL2018000246A1
CL2018000246A1 CL2018000246A CL2018000246A CL2018000246A1 CL 2018000246 A1 CL2018000246 A1 CL 2018000246A1 CL 2018000246 A CL2018000246 A CL 2018000246A CL 2018000246 A CL2018000246 A CL 2018000246A CL 2018000246 A1 CL2018000246 A1 CL 2018000246A1
Authority
CL
Chile
Prior art keywords
tablet
competient
acid
active ingredients
present
Prior art date
Application number
CL2018000246A
Other languages
English (en)
Inventor
Arisa Maeda
Yuichi Sugiyama
Yoshihiro Uchiyama
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2018000246A1 publication Critical patent/CL2018000246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UNA TABLETA EN LA CUAL LA ESTABILIDAD DE LOS INGREDIENTES ACTIVOS (UN BLOQUEADOR DE ÁCIDO COMPETITIVO CON EL ION DE POTASIO Y ÁCIDO ACETILSALICÍLICO) ES ALTA Y LAS ACTIVIDADES FARMACOLÓGICAS DE LOS INGREDIENTES ACTIVOS SE PUEDEN EJERCER DE MANERA ESTABLE Y RÁPIDA D-ESPUÉS DE LA ADMINISTRACIÓN DE LA TABLETA. LA PRESENTE INVENCIÓN SE REFIERE A UNA TABLETA CON REVESTIMIENTO ENTÉRICO QUE TIENE UN NÚCLEO INTERIOR Y UNA CAPA EXTERIOR, EN DONDE EL NÚCLEO INTERIOR CONTIENE ÁCIDO ACETILSALICÍLICO Y LA CAPA EXTERIOR CONTIENE UN BLOQUEADOR DE ÁCIDO COMPETITIVO CON EL ION DE POTASIO QUE NO ESTÁ REVESTIDO ENTÉRICAMENTE.</p>
CL2018000246A 2015-07-30 2018-01-26 Tableta CL2018000246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015151336 2015-07-30

Publications (1)

Publication Number Publication Date
CL2018000246A1 true CL2018000246A1 (es) 2018-06-29

Family

ID=57884505

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000246A CL2018000246A1 (es) 2015-07-30 2018-01-26 Tableta

Country Status (19)

Country Link
US (1) US10835541B2 (es)
EP (1) EP3329921B1 (es)
JP (1) JP6778680B2 (es)
CN (1) CN108135915B (es)
BR (1) BR112018001859B1 (es)
CA (1) CA2994073C (es)
CL (1) CL2018000246A1 (es)
CO (1) CO2018000991A2 (es)
CR (1) CR20180119A (es)
EC (1) ECSP18015616A (es)
ES (1) ES2977953T3 (es)
MX (1) MX386414B (es)
MY (1) MY189306A (es)
PE (1) PE20180605A1 (es)
PH (1) PH12018500236B1 (es)
SG (2) SG10201914087UA (es)
TW (1) TWI710379B (es)
UA (1) UA124663C2 (es)
WO (1) WO2017018473A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200542A (en) * 2017-07-10 2024-01-02 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
EP4271365A4 (en) * 2020-12-30 2024-12-25 HK inno.N Corporation Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs
CN114762687A (zh) * 2021-01-11 2022-07-19 上海天慈生物谷生物工程有限公司 一种钾离子竞争性酸阻滞剂的预混物及其制备
CN116966180B (zh) * 2022-11-10 2024-05-14 山东道合药业有限公司 沃诺拉赞焦谷氨酸盐的片剂、注射剂、复方制剂
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN118236338B (zh) * 2024-05-29 2024-09-17 寿光富康制药有限公司 一种富马酸伏诺拉生制剂的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2163241A1 (en) 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
DE10317023A1 (de) 2003-04-11 2004-11-11 Altana Pharma Ag Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten
SA04250092B1 (ar) 2003-05-14 2008-05-04 التانا فاروا ايه جي مركب وسيط جديد لتحضير مركبات إيميدازوبيريدين imidazopyridines فعالة علاجياً
AU2004285394B2 (en) 2003-11-03 2009-01-08 Astrazeneca Ab Imidazo (1,2-A) pyridine derivatives for the treatment of silent gastro-esophageal reflux
CA2554271A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
WO2007125397A2 (en) 2006-04-27 2007-11-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
CN102743330B (zh) 2008-07-28 2016-03-23 武田药品工业株式会社 药物组合物
MY152008A (en) 2008-08-27 2014-08-15 Takeda Pharmaceutical Pyrrole compounds
US20100305163A1 (en) 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
PH12012502153A1 (en) 2010-04-30 2013-02-04 Takeda Pharmaceuticals Co Enteric tablet
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CN105412038A (zh) * 2015-12-11 2016-03-23 北京阜康仁生物制药科技有限公司 一种包含沃诺拉赞和非甾体抗炎药的复方制剂

Also Published As

Publication number Publication date
ES2977953T3 (es) 2024-09-03
CO2018000991A2 (es) 2018-05-10
UA124663C2 (uk) 2021-10-27
EP3329921B1 (en) 2024-03-27
ECSP18015616A (es) 2018-07-31
WO2017018473A1 (ja) 2017-02-02
SG11201800591TA (en) 2018-02-27
EP3329921A4 (en) 2019-03-27
CN108135915A (zh) 2018-06-08
US10835541B2 (en) 2020-11-17
MY189306A (en) 2022-02-03
SG10201914087UA (en) 2020-03-30
CN108135915B (zh) 2021-06-25
TWI710379B (zh) 2020-11-21
PE20180605A1 (es) 2018-04-09
PH12018500236B1 (en) 2023-12-06
TW201714608A (zh) 2017-05-01
HK1249857A1 (en) 2018-11-16
EP3329921A1 (en) 2018-06-06
CA2994073C (en) 2023-09-05
PH12018500236A1 (en) 2018-08-13
US20180214460A1 (en) 2018-08-02
BR112018001859B1 (pt) 2023-05-02
CA2994073A1 (en) 2017-02-02
MX386414B (es) 2025-03-18
KR20180030412A (ko) 2018-03-22
CR20180119A (es) 2018-03-21
BR112018001859A2 (pt) 2018-11-27
MX2018001209A (es) 2018-07-06
JP6778680B2 (ja) 2020-11-04
JPWO2017018473A1 (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
CL2018000246A1 (es) Tableta
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2017003089A1 (es) Formas de dosificación sólidas de palbociclib
CR20160192A (es) Formulación de farmaco de liberación retardada
BR112016007375A2 (pt) conjuntos de procedimentos para habilitar comunicações sem fio com o uso de estruturas de subquadro que tenham diferentes durações de subquadro
CR20140485A (es) Formulacion de farmaco de liberacion retardada
AR099591A1 (es) Acelerador de cemento pasivado
CR20230300A (es) ANTICUERPOS PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS (Divisional expediente 2018-0021)
MX2021011676A (es) Polimorfos de sepiapterina y sales de los mismos.
MX2018003297A (es) Aplicador de precision.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2017000271A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX388313B (es) Formulacion que comprende un profarmaco de gemcitabina
IL253619A0 (en) Encapsulation of high potency active agents
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
DOP2016000064A (es) Derivados de fenilalanina sustituidos
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
CL2018001129A1 (es) Parche adhesivo con huecos
MX2017011934A (es) Formas solidas de menaquinoles.
MX2015014307A (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
CL2017000582A1 (es) Nuevos compuestos derivados de piridopirimidinas
Борисов et al. Studying the structure of thermal barrier plasma coating with nuclear backscattering spectrometry
MX2018002449A (es) Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas.